Studies have found that mutations in BMAL1, CRY1, and CRY2 are often associated with a higher risk and recurrence of acute myeloid leukemia and endometrial, ovarian, colorectal, and breast cancers (Hasakova et al., 2018; Burgermeister et al., 2019; Kwon et al., 2020). This evidence concerns the gene CRY1 and breast cancer.